Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

被引：21
|
作者：
Zobniw, Chrystia M. [1 ]
Causebrook, Alanna [2 ]
Fong, Mei Ka [1 ]
机构：
[1] Roswell Pk Canc Inst, Dept Pharm, Elm & Carlton St, Buffalo, NY 14263 USA
[2] Erie Coll Osteopath Med, Sch Pharm, Erie, PA USA
来源：
RESEARCH AND REPORTS IN UROLOGY | 2014年 / 6卷
关键词：
glucocorticoid receptor; CYP17; pipeline; enzalutamide; sipuleucel-T; drug resistance; radium-223; dichloride;
D O I：
10.2147/RRU.S29003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
引用
收藏
页码：97 / 105
页数：9
相关论文
共 50 条
  • [1] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [2] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [3] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [4] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
    Lily P. H. Yang
    Drugs, 2011, 71 : 2067 - 2077
  • [5] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Lily P. H. Yang
    Katherine A. Lyseng-Williamson
    Drugs & Aging, 2012, 29 : 243 - 248
  • [6] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    Yang, Lily P. H.
    Lyseng-Williamson, Katherine A.
    DRUGS & AGING, 2012, 29 (03) : 243 - 248
  • [7] The role of abiraterone in the management of metastatic castration-resistant prostate cancer
    Rawlinson, Alex
    Mohammed, Aza
    Beatty, John
    Bell, Richard
    Miller, Marek
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 429 - 437
  • [8] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [9] New drugs in the treatment of metastatic castration-resistant prostate cancer: abiraterone acetate
    Martinez-Hernandez, Lucia
    Martinez-Prieto, Marcela
    Galvan-Salazar, Gabriel
    GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (01): : 32 - 40
  • [10] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
12345